RxDoctor Payments Data

Piotr Kloda, MD

Internal Medicine · Dublin, OHNPI 1821107715

Payments from drug & device makers

$592in general payments, 2019–2025

Across 31 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$98
  • Boston Scientific$67
  • AstraZeneca$63
  • Pfizer$51
  • Corcept Therapeutics$44
  • Xeris Pharmaceuticals, Inc.$39
  • plus $230 from 9 others

What the payments were for

  • Food & beverage$57898%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$592 in reported general payments places this provider in the 65th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$142,825
Medicare patients
230
Services billed
8,975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate59$76,295
EliquisApixaban64$71,827
OzempicSemaglutide36$43,380
Janumet XrSitagliptin Phos/Metformin Hcl29$43,039
JardianceEmpagliflozin24$37,052
XareltoRivaroxaban27$30,844
TrulicityDulaglutide12$20,367
MounjaroTirzepatide19$19,643
Tresiba Flextouch U-100Insulin Degludec22$16,021
Breo ElliptaFluticasone/Vilanterol23$14,575
InvokanaCanagliflozin12$12,826
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,494
Lantus SolostarInsulin Glargine,hum.Rec.Anlog62$7,177
VascepaIcosapent Ethyl11$3,831
Atorvastatin Calcium397$3,483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$51$71,82764 claims
Johnson & JohnsonXarelto, Invokana$16$43,67039 claims
Novo NordiskOzempic$98$43,38036 claims
Lilly USA, LLCTrulicity, Mounjaro$21$40,01131 claims
GSKBreo Ellipta, Trelegy Ellipta$35$22,06935 claims
AbbVieSynthroid$35$2,18063 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Dublin

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →